60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State




60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State

• Further validates continuation of the B-FREE Study to evaluate the efficacy and safety of ARAKODA^® (tafenoquine) for treatment of chronic babesiosis
• Data support theory among specialists that Babesia infection may prolong recovery times in patients with chronic fatigue

WASHINGTON, Dec. 29, 2025 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that infection with Babesia, a parasite that causes the emerging tick-borne illness called babesiosis, was found in 24 percent of a cohort of 50 patients with chronic fatigue in a study conducted by researchers at North Carolina State University, and published in Pathogens.

Results announced today contribute to efforts to confirm a long-held theory within the U.S. vector-borne disease community that Babesia and chronic disease may be linked – specifically, that Babesia infection may prolong recovery times in patients with chronic fatigue.

The results also reinforce the importance of the B-Free Chronic Babesiosis Study (NCT06656351), which is evaluating efficacy and safety of the ARAKODA regimen of tafenoquine over 90 days for resolution of severe fatigue in patients with chronic babesiosis. The Company’s B-Free Study is now enrolling at the Icahn School of Medicine at Mount Sinai in New York.

“Healthcare providers who treat tick-borne illness may not be surprised by the results of this study,” said 60 Degrees Pharma Chief Executive Officer, Geoffrey Dow. “While the results don’t prove that Babesia infection causes chronic disease, they are consistent with that hypothesis and highlight the need for prospective controlled studies which the Company is now undertaking.”

Tafenoquine is approved for malaria prophylaxis in the United States under the product name ARAKODA^®. Tafenoquine has not been proven to be effective for treatment or prevention of babesiosis and is not approved by the United States Food and Drug Administration for such an indication.

About the North Carolina State University Chronic Fatigue Study

The study involved a cohort of 50 participants selected from a group of 173 individuals who self-reported a history of chronic diseases and potential exposure to arthropod vectors. Participants had all experienced fatigue for at least six months with concurrent neurological symptoms. Participants provided three blood samples over a week, which were archived and later cultured and tested for Babesia DNA using PCR assays.

The study was conducted under an Institutional Review Board (IRB)-approved protocol and was funded in part by 60 Degrees Pharma.

About Babesiosis
Babesiosis is a tick-borne illness caused by Babesia parasites that develop and multiply in red blood cells. Its symptoms include fevers, chills, sweats, and fatigue, and in severe cases, can be life-threatening in elderly and immunosuppressed patients. Incidence of the disease is rapidly rising, particularly in the Northeast. Transmitted through the bite of the black-legged (deer) tick, the vector that spreads Lyme disease, babesiosis is an orphan disease. Insurance claims research commissioned by the Company suggest that the minimum annual incidence of babesiosis is at least 25,000 cases per year, although the true number may be much larger than this. Currently no U.S. Food and Drug Administration (FDA)-approved treatment exists specifically for babesiosis.

Babesia infection persists for months, and potentially for several years, following a tick bite. In patients with risk factors (e.g., immunosuppression, age, asplenia), persistent infection may result in recurring clinical relapses of the disease, each with the potential for hospitalization. In individuals without such known risk factors, it has been generally assumed that persistent infection is not clinically meaningful. However, the potential clinical significance of persistent infection in individuals with dysregulated immune systems (e.g., chronic tick-borne diseases, long Covid and other long syndromes) has not been studied, but is hypothesized to complicate recovery from other chronic symptoms. The lack of sufficiently sensitive, FDA-approved diagnostics has stymied efforts to study this problem.

About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved U.S. Food and Drug Administration approval of Its lead product, ARAKODA^® (tafenoquine), for malaria prevention in 2018. ARAKODA is commercially available in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research and academic organizations in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.

The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.

Cautionary Note Regarding Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA^® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials or patient recruitment in our trials might be slow or negligible; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward- looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on April 1, 2024, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s website at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Media Contact:
Sheila A. Burke
SheilaBurke-consultant@60degreespharma.com
(484) 667-6330

Investor Contact:
Patrick Gaynes
patrickgaynes@60degreespharma.com

BiomX Announces $3.0 Million Private Placement




BiomX Announces $3.0 Million Private Placement

Proceeds to Support the Company’s Assessment of Opportunities to Advance BX011 and Ongoing Evaluation of Strategic Alternatives

NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity (“Private Placement”) financing for expected gross proceeds of approximately $3.0 million, before deducting placement agent fees and other offering expenses.

H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement.

About the Private Placement
In the Private Placement, the Company agreed to issue and sell shares of its Series Y Convertible Preferred Stock, with a stated value of $1,000 per share, together with warrants (collectively, the “Securities”) with an aggregate stated value of up to $3.3 million, for an aggregate purchase price of $3.0 million.

Each share of Series Y Convertible Preferred Stock will accrue dividends at a rate of 15% per annum, payable quarterly, and will have a maturity of one year from the closing date. The Series Y Convertible Preferred Stock will be convertible into shares of the Company’s common stock, subject to the limitations set forth in the definitive agreements, including the receipt of stockholder approval to the extent required under NYSE American rules.

In connection with the Private Placement, the Company will also issue warrants to acquire up to 3,300,000 shares of the Company’s common stock. The warrants will have a five-year term and an exercise price initially equal to $2.00, the applicable conversion price of the Series Y Convertible Preferred Stock, subject to certain adjustments if stockholder approval is obtained.

The Private Placement is expected to close on or about December 30, 2025, subject to the satisfaction of customary closing conditions.

The Securities sold in the Private Placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws, and were offered and sold in reliance on exemptions from the registration requirements of the Securities Act. The Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issuable upon conversion of the Series Y Convertible Preferred Stock and exercise of the warrants.

The Company intends to use the net proceeds from the private placement to support its assessment of opportunities across its bacteriophage programs, including BX011 for Staphylococcus aureus infections associated with diabetic foot infections, and for general corporate purposes, including providing operational flexibility while the Company continues to evaluate strategic alternatives.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any Securities, nor shall there be any sale of Securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.

Safe Harbor
This press release contains express or implied “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters.  For example, when BiomX refers to the anticipated closing of the Private Placement and timing thereof, the intended use of the net proceeds, the receipt of stockholder approval, the evaluation of opportunities related to its clinical programs, including BX011, the timing and design of potential future development activities, and its ongoing assessment of strategic alternatives, it is using forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management’s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of BiomX’s control. These risks and uncertainties include, but are not limited to, market and other conditions, BiomX’s ability to obtain all necessary regulatory approvals on a timely basis, or at all; BiomX’s ability to obtain stockholder approval on a timely basis, or at all; the closing of the private placement on a timely basis on the terms described herein, or at all; changes in applicable laws or regulations; the possibility that BiomX may be adversely affected by other economic, business, and/or competitive factors, including risks inherent in pharmaceutical research and development, such as: adverse results in BiomX’s drug discovery, preclinical and clinical development activities, the risk that the results of preclinical studies and early clinical trials may not be replicated in later clinical trials, BiomX’s ability to enroll patients in its clinical trials, and the risk that any of its clinical trials may not commence, continue or be completed on time, or at all; decisions made by the FDA and other regulatory authorities; investigational review boards at clinical trial sites and publication review bodies with respect to our development candidates; BiomX’s ability to obtain, maintain and enforce intellectual property rights for its platform and development candidates; its potential dependence on collaboration partners; competition; uncertainties as to the sufficiency of BiomX’s cash resources to fund its planned activities for the periods anticipated and BiomX’s ability to manage unplanned cash requirements; and general economic and market conditions. Therefore, investors should not rely on any of these forward-looking statements and should review the risks and uncertainties described under the caption “Risk Factors” in BiomX’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 25, 2025, and additional disclosures BiomX makes in its other filings with the SEC, which are available on the SEC’s website at www.sec.gov. Forward-looking statements are made as of the date of this press release, and except as provided by law BiomX expressly disclaims any obligation or undertaking to update forward-looking statements.

Contacts:

BiomX, Inc.
Ben Cohen
Head Corporate Communications
benc@biomx.com

Inspire Medical Systems, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference




Inspire Medical Systems, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference

MINNEAPOLIS, Dec. 29, 2025 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the 44^th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026.

Inspire is scheduled to present at 12:45 p.m. Eastern Time. The presentation will be accessible via a live webcast here.

A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire’s Investor website at https://investors.inspiresleep.com.

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum




Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Sachs 9^th Annual Neuroscience Innovation Forum, taking place January 11, 2026, in San Francisco, CA.

Presentation Details:

Format: Corporate Presentation
Date: Sunday, January 11, 2026
Time: 1:20 PM PT
Presenter: Laxminarayan Bhat, Ph.D., Reviva Pharmaceuticals
Location: Marines’ Memorial Club, San Francisco, CA

About Reviva 
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD 
www.revivapharma.com

Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor




Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential tremor

Praxis remains on track to submit ulixacaltamide NDA in early 2026 based on recently completed pre-NDA meeting with the FDA

BOSTON, Dec. 29, 2025 (GLOBE NEWSWIRE) —  Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for ulixacaltamide, a differentiated and highly selective small molecule inhibitor of T-type calcium channels, for the treatment of patients with essential tremor (ET).

“The granting of the Breakthrough Therapy Designation for ulixacaltamide, based on the Essential3 program, further underscores its potential to address the substantial unmet need in patients with ET. We recently completed a series of positive interactions with the FDA, that, together with this BTD, are enabling us to advance this promising treatment faster to patients. We are diligently preparing for the filing of the ulixacaltamide NDA, which we expect in early 2026,” said Marcio Souza, president and chief executive officer.

The BTD enables expedited development and regulatory review for drugs that are intended to treat a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over available therapies. The BTD for ulixacaltamide was based on the positive topline data from the Essential3 program, consisting of two pivotal Phase 3 studies of ulixacaltamide in ET.

In December 2025, Praxis announced the successful completion of its pre-NDA meeting with the FDA, including the receipt of written feedback and an in-person meeting. The Company has aligned with the FDA on the content of the NDA and expects to submit the ulixacaltamide NDA in early 2026.

About Essential Tremor (ET)
Essential Tremor is the most common movement disorder, affecting roughly seven million people in the United States alone, representing a multi-billion dollar commercial opportunity. ET is characterized by involuntary rhythmic movement in the upper limbs, with or without tremor in other body locations such as the head, vocal cords, or legs. These tremors significantly disrupt daily living and are progressive in nature, with increases in tremor severity and amplitude commonly observed over the course of the disease. Propranolol, a beta-blocker, is the only approved pharmacotherapy for ET, offering limited efficacy and poor tolerability and is also contraindicated for comorbidities that affect a significant share of the ET population. Other beta blockers and anti-convulsants are used off-label, though similarly are characterized by limited efficacy and tolerability. The vast majority of patients are left without a treatment option, with estimated minimum of 2 million patients seeking treatment. In a patient survey, up to 77% of patients felt their ET is inadequately controlled and up to 50% of patients aren’t receiving treatment. Indeed, U.S. neurologists surveyed indicated that 85% of their visits are for patients seeking treatment, and 40% of their patients are not receiving any treatment. These findings underscore the need for more effective treatments for ET.

About Ulixacaltamide
Ulixacaltamide is a differentiated and highly selective small molecule inhibitor of T-type calcium channels designed to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical (CTC) circuit correlated with tremor activity. Ulixacaltamide is the most advanced program within Praxis’ Cerebrum™ small molecule platform.

About Praxis  
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding Praxis’ future expectations, plans and prospects, including, without limitation, statements regarding the development of Praxis’ product candidates and the anticipated timing of regulatory submissions and interactions, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “endeavor,” “estimate,” “expect,” “anticipate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would” and similar expressions that constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995.

The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical trials; the expected timing of clinical trials, data readouts and the results thereof, and submissions for regulatory approval or review by governmental authorities; regulatory approvals to conduct trials; and other risks concerning Praxis’ programs and operations as described in its Annual Report on Form 10-K for the year ended December 31, 2024 and as updated in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, as well as other filings made with the Securities and Exchange Commission. Although Praxis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on information and factors currently known by Praxis. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Praxis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

CONTACT: Investor Contact: 
Praxis Precision Medicines 
investors@praxismedicines.com 
857-702-9452 
 
Media Contact:
Dan Ferry
Life Science Advisors
Daniel@lifesciadvisors.com
617-430-7576

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma




HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma

— NDA supported by results from a Phase II registration trial in China —

— Second most common form of liver cancer after hepatocellular carcinoma, with generally poorer long-term survival in comparison —

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the New Drug Application (“NDA”) for fanregratinib (HMPL-453) for the treatment of adult patients with advanced, metastatic or unresectable intrahepatic cholangiocarcinoma (“ICC”) with fibroblast growth factor receptor (“FGFR”) 2 fusion/rearrangement who have previously received systemic therapy has been accepted and granted priority review by the China National Medical Products Administration (“NMPA”).

Fanregratinib (HMPL-453) is a novel, selective, oral inhibitor targeting FGFR 1/2/3. ICC is a highly aggressive malignancy arising from the intrahepatic biliary epithelium. It accounts for 8.2-15.0% of primary liver cancers, and consequently it is the second most common type after hepatocellular carcinoma. In recent years, the incidence of ICC has continued to rise, with a 5-year overall survival rate of approximately 9%.¹ Approximately 10-15% of ICC patients globally have tumors harboring FGFR2 fusions or rearrangements.^2,3

This NDA is supported by data from a single-arm, multi-center, open-label, Phase II registration study in China. The study has met its primary endpoint of objective response rate (ORR). Results from the secondary endpoints including progression-free survival (PFS), disease control rate (DCR), duration of response (DoR) and overall survival (OS) also support the primary endpoint findings. Full results will be submitted for presentation at an upcoming scientific conference. Additional details may be found at clinicaltrials.gov using identifier NCT04353375.

About Fanregratinib

Fanregratinib (HMPL-453) is a novel, highly selective and potent inhibitor targeting FGFR 1, 2 and 3. Aberrant FGFR signaling has been found to be a driving force in tumor growth, promotion of angiogenesis and resistance to anti-tumor therapies. Abnormal FGFR gene alterations are believed to be the drivers of tumor cell proliferation in several solid tumor settings. HUTCHMED currently retain all rights to fanregratinib worldwide.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the review of a NDA for fanregratinib for the treatment of ICC with the NMPA and the timing of such review, therapeutic potential of fanregratinib for the treatment of patients with ICC and the further development of fanregratinib in this and other indications. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the timing and outcome of clinical studies and the sufficiency of clinical data to support NDA approval of fanregratinib for the treatment of patients with ICC or other indications in China or other jurisdictions, its potential to gain approvals from regulatory authorities on an expedited basis or at all, the safety profile of fanregratinib, HUTCHMED’s ability to fund, implement and complete its further clinical development and commercialization plans for fanregratinib and the timing of these events. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

¹ Expert consensus on precision detection of intrahepatic cholangiocarcinoma (2024 edition). Chin J Clin Med. 2025;32(1):1-18.
² Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59:1427–34.
³ Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47:1003–10.

Transcenta Therapeutics Announces Strategic Collaboration and Non-exclusive Licensing Agreement to Advance Integrated Continuous Biomanufacturing and Expand Global Access to Affordable Biologics




Transcenta Therapeutics Announces Strategic Collaboration and Non-exclusive Licensing Agreement to Advance Integrated Continuous Biomanufacturing and Expand Global Access to Affordable Biologics

PRINCETON, N.J. and HANGZHOU, China, Dec. 28, 2025 (GLOBE NEWSWIRE) — Transcenta Holding Limited (HKEX: 06628) (“Transcenta Therapeutics”), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced it has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. (“EirGenix”) (TWSE: 6589), a global biopharmaceutical development and manufacturing company.

Under the agreement, Transcenta will grant EirGenix a non-exclusive license to use its Highly Intensified Continuous Bioprocessing (HiCB) platform, including highly productive continuous perfusion and integrated hybrid continuous purification process technologies, along with comprehensive process documentation, know-how, and regulatory support packages. Transcenta will be eligible to receive a substantial upfront and milestone payments, as well as future royalty payments associated with the commercial use of the licensed technologies, reflecting the long-term value both companies expect to create through this collaboration.

The HiCB platform is designed to deliver greater process efficiency, improve process control and product consistency, and significantly reduce cost of goods compared to conventional fed-batch manufacturing process, ultimately contributing to expanded global patient access to high-quality, affordable biologics.

Under this collaboration, EirGenix will adopt Transcenta’s HiCB platform to support its biologics development programs and manufacturing operations. EirGenix plans to apply the HiCB platform to serve CDMO clients pursuing intensified and continuous manufacturing solutions.

“We are pleased to share our HiCB platform, a result of Transcenta’s leadership in highly intensified continuous bioprocessing, with partners who share our vision of transforming biologics manufacturing,” said Dr. Xueming Qian, Chairman and CEO of Transcenta. “By enabling others to implement HiCB, we can collectively advance affordability of and global access to innovative biologics. The proceeds from this and future collaborations will be reinvested to further strengthen our technology platform and advance our R&D pipeline to deliver next-generation, best-in-class therapeutics.”

“This collaboration represents a win–win partnership that combines Transcenta’s innovation in continuous biomanufacturing and EirGenix’s proven bioprocessing and CDMO expertise,” said Dr. L.-C. Liu, Chairman and President of EirGenix. “Together, we aim to redefine how biologics are made—more efficiently, sustainably, and at lower cost—to reach more patients worldwide.”

About Transcenta Therapeutics
Transcenta (HKEX: 06628) is a global clinical stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, development and manufacturing.

Transcenta has established global footprint, with Headquarters and Discovery, Clinical and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in China, U.S. and Europe. Transcenta is developing a diverse pipeline of more than a dozen novel biologic therapies for oncology and selected non-oncology indications including bone and kidney disorders.

For more information, please visit www.transcenta.com and https://www.linkedin.com/company/transcenta. For inquiries regarding Business Development opportunities, please contact us at bd@transcenta.com

About EirGenix
EirGenix, Inc. is Taiwan’s largest biologics CDMO, providing comprehensive services from cell line and process development to GMP manufacturing and analytical testing. With globally recognized quality systems and regulatory approvals, we deliver reliable biomanufacturing solutions to global partners. Alongside our CDMO business, EirGenix is advancing its own biosimilar and ADC pipeline, focusing on antibody therapeutics for oncology and other diseases. At EirGenix, Clients’ Success is Our Priority, and we strive to make innovative, high-quality biologics accessible worldwide.

For more information, please visit www.eirgenix.com and https://www.linkedin.com/company/eirgenix. For inquiries regarding Business Development opportunities, please contact us at service@eirgenix.com

BioSonic Bloom: What Published Research Says About 528 Hz and 432 Hz Audio Frequency Programs




BioSonic Bloom: What Published Research Says About 528 Hz and 432 Hz Audio Frequency Programs

An In-Depth Analysis of Digital Sound Frequency Programs, Binaural Beats Research, and Key Considerations for 2026

Detroit, MI, Dec. 27, 2025 (GLOBE NEWSWIRE) — Disclaimer: This article is for informational purposes only and does not constitute medical or psychological advice. Individual experiences with audio frequency programs vary significantly. This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy or integrity of the information presented.

As interest in audio-based wellness practices continues to develop, programs utilizing specific sound frequencies have attracted attention among individuals exploring relaxation and mindfulness-oriented listening experiences. One such program, BioSonic Bloom, employs 528 Hz and 432 Hz frequencies, which have been examined in peer-reviewed research exploring responses to sound exposure under controlled conditions.

This analysis examines what BioSonic Bloom offers, the current research landscape surrounding its core frequencies, and considerations for those evaluating whether audio frequency programs align with their personal interests.

View the current BioSonic Bloom offer

Examining Published Research on Sound Frequencies

Before evaluating any specific audio program, understanding the current state of published research provides important context.

528 Hz Frequency Research

The 528 Hz frequency has been examined in several peer-reviewed studies exploring responses to sound exposure:

A 2018 study published in the journal Health by researchers Akimoto, Hu, Yamaguchi, and Kobayashi examined participants exposed to 528 Hz tones. According to this research, the study explored potential relationships between frequency exposure and certain physiological markers under controlled laboratory conditions.

Research published in Genes and Genomics (2018) by Daylari and colleagues examined sound waves at 528 Hz frequency in laboratory settings. The researchers reported observations regarding biological markers, though the study authors noted limitations in extrapolating findings.

A 2017 study in the Journal of Addiction Research and Therapy by Babayi and Riazi explored the effects of 528 Hz sound waves on cell cultures in controlled laboratory environments.

A 2024 study published in Revista Electronica de Veterinaria examined 528 Hz exposure and self-reported anxiety measures in a small participant sample. The researchers reported differences between experimental and control groups while noting the preliminary nature of findings.

432 Hz Frequency Research

The 432 Hz frequency has also been examined in clinical research settings:

A double-blind pilot study published in Acta Bio Medica (2020) by Calamassi and colleagues compared music tuned to 432 Hz versus 440 Hz. According to this research, participants reported subjective differences between the two tuning frequencies, with researchers noting the need for larger-scale studies.

Research published in Frontiers in Public Health (2022) examined individuals who listened to music at 432 Hz versus 440 Hz. The study explored relationships between frequency exposure and certain physiological measurements under controlled conditions.

A clinical study published in the Journal of Clinical and Diagnostic Research (2020) examined participants exposed to 432 Hz music in a dental setting. Researchers measured salivary cortisol levels and reported observations while acknowledging study limitations.

Binaural Beats Research

Binaural beats—created when slightly different frequencies are presented to each ear—have been studied more extensively:

A meta-analysis published in Psychological Research (2019) by Garcia-Argibay and colleagues examined multiple studies on binaural beat exposure. According to this meta-analysis, findings varied across studies, with researchers noting that outcomes appeared to depend on frequency used, exposure duration, and timing protocols.

A systematic review published in PLOS ONE (2023) examined research on binaural beat stimulation. The reviewers noted considerable methodological heterogeneity across studies, concluding that while research spans approximately fifteen years across multiple institutions, standardized protocols have not been established.

Research published in Healthcare (2024) examined binaural beats in specific clinical contexts, noting that while some studies showed differences between experimental and control groups, further research is needed regarding optimal protocols.

What BioSonic Bloom Offers

According to the company’s website, BioSonic Bloom is a structured digital audio format that the company states is organized around specific sound frequencies commonly discussed in academic and wellness research.

Program Components

Per the company’s published materials:

Audio Format: Digital audio tracks incorporating 528 Hz and 432 Hz frequencies with binaural beat elements.

Listening Duration: According to the company, the suggested listening duration is 30 minutes per session.

Digital Delivery: The program is delivered as downloadable digital files accessible from various devices.

Additional Materials: According to the company website, purchasers receive supplementary audio content.

Availability Information

According to the company’s publicly available website, the digital program is currently listed at a one-time purchase price. Pricing, availability, and policies are subject to change and should be confirmed directly on the official website before making any purchase decision.

View the current BioSonic Bloom offer

Evaluating Audio Frequency Programs: Considerations

For those exploring audio-based practices, several factors warrant consideration when evaluating any program in this category.

This Category May Interest Individuals Who:

Are Exploring Relaxation-Oriented Practices: Those interested in audio-based approaches to relaxation and mindfulness may find frequency programs one option among many to explore.

Have Interest in Sound-Based Research: Individuals who follow developments in sound frequency research may find programs incorporating studied frequencies relevant to their interests.

Prefer Structured Listening Formats: For those who prefer curated audio content rather than searching across various platforms, structured programs offer organizational convenience.

Prefer Digital Accessibility: The digital delivery format may appeal to those seeking portable, device-accessible audio content.

Approach with Exploratory Expectations: Those who understand that research in this area continues to develop—rather than offering definitive conclusions—may approach such programs with appropriate perspective.

Alternative Approaches May Suit Individuals Who:

Prioritize Extensively Validated Approaches: Those seeking practices with extensive clinical validation and established protocols may find the current research landscape in this area insufficient for their preferences.

Experience Significant Stress or Mental Health Concerns: Individuals dealing with significant concerns should prioritize working with qualified professionals rather than relying on audio programs.

Expect Specific Guaranteed Outcomes: Audio frequency programs, like most wellness-oriented products, produce varying subjective experiences across different individuals.

Prefer No-Cost Options: Various frequency audio content is available at no cost on platforms such as YouTube and Spotify. Those prioritizing cost considerations may prefer exploring freely available options.

Questions for Personal Evaluation

Before exploring any audio-based program, consider:

• Am I approaching this as an exploratory interest rather than seeking a specific outcome?
• Am I comfortable with research that is developing rather than conclusive?
• Do I have realistic expectations about subjective listening experiences?
• Have I consulted with appropriate professionals regarding any significant concerns?

Honest reflection on these questions can help determine alignment with individual circumstances.

Understanding Research Context and Limitations

Responsible evaluation requires acknowledging what current research does and does not establish:

What Published Research Examines:

• Specific frequencies including 528 Hz and 432 Hz have been subjects of peer-reviewed studies
• Some studies report observations regarding physiological markers and self-reported measures
• Binaural beats have been examined across multiple research institutions over approximately fifteen years
• Several studies explore potential relationships between frequency exposure and relaxation-related measures

What Research Has Not Established:

• Large-scale clinical trials with extensive participant populations
• Standardized protocols for optimal frequency, duration, and application
• Long-term outcome studies
• Mechanisms fully explaining observed phenomena
• Definitive conclusions regarding efficacy for specific applications

According to a systematic review published in PLOS ONE (2023), researchers noted considerable methodological heterogeneity across studies in this field. The reviewers observed that while frequency-based audio stimulation has been researched for nearly two decades, the research landscape continues to develop.

This context is important: published research exists and explores interesting questions, but definitive conclusions have not been established.

Approaching Audio Frequency Programs Thoughtfully

For those interested in exploring audio frequency programs, a measured approach may be helpful:

Maintain Appropriate Perspective: View audio frequency programs as exploratory practices rather than established interventions.

Continue Professional Relationships: Audio programs should not replace professional care. Continue working with qualified providers for any health-related concerns.

Allow Adequate Exploration Time: Subjective experiences with audio-based practices may develop over time rather than immediately.

Note Personal Responses: Individual responses vary. Personal observation over time may help evaluate subjective value.

Verify Current Information: Availability, pricing, and terms change. Always confirm current details on official websites before any purchase.

View current BioSonic Bloom information

The Audio Frequency Category Landscape

BioSonic Bloom operates within a broader category of audio-based programs. Understanding available options provides useful context:

Freely Available Content: Platforms like YouTube and Spotify offer extensive 528 Hz, 432 Hz, and binaural beat content at no cost. These options provide accessible exploration without financial commitment.

Meditation Applications: Applications such as Calm, Headspace, and Insight Timer incorporate various audio elements within broader program offerings.

Structured Frequency Programs: Several commercial programs focus specifically on frequency-based audio, with varying formats and included content.

Professional Sound Therapy: Licensed practitioners offer in-person sessions using various instruments and tools.

Each approach offers different characteristics regarding cost, convenience, curation, and professional guidance. Individual preferences and priorities determine which approach makes most sense for specific circumstances.

Summary Considerations

BioSonic Bloom represents one option within the category of audio frequency programs. Its incorporation of 528 Hz and 432 Hz frequencies—both of which have been examined in peer-reviewed research—provides context that distinguishes structured programs from offerings without any research foundation.

Simultaneously, responsible evaluation acknowledges that research in this area continues to develop. Published studies explore interesting questions and report various observations, but standardized protocols and definitive conclusions have not been established.

For individuals interested in exploring audio frequency programs as one element of broader relaxation-oriented practices—with exploratory expectations and continued engagement with appropriate professionals as needed—programs like BioSonic Bloom represent one structured option available for consideration.

Those evaluating this or any audio frequency program should verify current availability and terms directly with the company, maintain realistic expectations, and prioritize working with qualified professionals for any significant concerns.

View current BioSonic Bloom availability

Contact Information

For questions regarding BioSonic Bloom, according to the company’s publicly available information:

BioSonic Bloom Email: support@biosonicbloom.com Address: 285 Northeast Ave, Tallmadge, Ohio 44278

Payment Processing (ClickBank) Email: support@clickbank.com Phone (US): +1 800-390-6035 Phone (International): +1 208-345-4245 Address: 1444 S. Entertainment Ave, Suite 410, Boise, Idaho 83709 USA

Disclaimers

Content Disclaimer: This article is for informational and educational purposes only. The information presented does not constitute medical, psychological, or professional health advice. Audio frequency programs are not intended to diagnose, treat, cure, or prevent any disease or medical condition. Always consult qualified healthcare professionals before beginning any new practice, especially if you have existing health conditions or concerns.

Research Context Disclaimer: The scientific studies referenced in this article represent published research in this field. Research on audio frequencies continues to develop. The cited studies have various sample sizes, methodologies, and limitations acknowledged by their authors. Readers interested in the research should review original study publications for complete methodology and findings. The presence of published research does not constitute proof of efficacy for any specific commercial product or application.

Individual Experience Disclaimer: Individual experiences with audio frequency programs vary significantly based on numerous factors. Subjective responses differ across individuals. No specific outcomes are promised, implied, or guaranteed.

Affiliate Disclosure: This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. All descriptions are based on published research and publicly available information from the company’s official website.

Pricing and Availability Disclaimer: All availability information mentioned was based on publicly available information at the time of publication (December 2025) and is subject to change without notice. Always verify current pricing, terms, and conditions on the official website before making any purchase decision.

Publisher Responsibility Disclaimer: The publisher of this article has made reasonable efforts to ensure accuracy based on available published research and publicly available company information. We do not accept responsibility for errors, omissions, changes in company offerings, or outcomes resulting from the use of information provided. Readers are encouraged to conduct independent research and verification before making decisions.

Publication Date: December 2025

CONTACT: Email: support@biosonicbloom.com
Email: support@clickbank.com 
Phone (US): +1 800-390-6035 
Phone (International): +1 208-345-4245

Best TRT Injection for 2026: Fridays Lists Prescription Testosterone in Injectable and Oral Formats as Men Compare Telehealth Hormone Options




Best TRT Injection for 2026: Fridays Lists Prescription Testosterone in Injectable and Oral Formats as Men Compare Telehealth Hormone Options

Independent analysis examines Fridays’ published TRT program structure, delivery format options, and what clinical research indicates for men evaluating prescription testosterone pathways heading into 2026.

IRVINE, Dec. 27, 2025 (GLOBE NEWSWIRE) — Disclaimer: This article is for informational purposes only and does not constitute medical advice. Testosterone replacement therapy requires evaluation and prescription by a licensed clinician. This article contains affiliate links; a commission may be earned at no additional cost to you. This compensation does not influence the information presented.

Searches for “best TRT injection” surge each December and January as men making New Year health commitments evaluate whether prescription testosterone therapy might address persistent symptoms they have been experiencing. This timing coincides with peak advertising spend from telehealth platforms, creating a wave of consumer research activity.

This analysis examines what publicly available program information reveals about the Fridays telehealth TRT platform, what clinical research indicates about testosterone therapy benefits and safety in men with confirmed low testosterone, and what factors men should consider when comparing prescription access pathways heading into 2026.

Context on “Best”: In this analysis, “best” reflects consumer search behavior and refers to evaluation criteria such as prescription eligibility requirements, delivery format options, lab monitoring structure, and transparency of publicly available program details. It does not mean clinical superiority, guaranteed results, or medical advice. TRT requires individualized evaluation and approval by a licensed clinician.

Men comparing telehealth pathways can view the current TRT program offer (official Fridays page) to confirm current availability, pricing, and clinical intake requirements. Availability, pricing, and eligibility are determined by licensed clinicians and may vary by state and individual medical evaluation.

Why “Best TRT Injection” Searches Surge in Late December and January

The concentration of TRT-related searches during this period reflects identifiable patterns in consumer behavior and advertising dynamics.

Resolution-driven health evaluation: The New Year represents a psychological inflection point when men often commit to addressing health concerns they have been postponing. Symptoms associated with low testosterone—fatigue, reduced motivation, difficulty with body composition, changes in libido—frequently surface as priorities during this reflection period.

Advertising intensity: Telehealth TRT platforms significantly increase advertising spend during resolution season, reaching men through social media, podcasts, and digital channels. This exposure prompts research activity as men seek to validate claims and compare options.

Telehealth accessibility: The continued expansion of telehealth has made prescription TRT evaluation more accessible than traditional clinic-based pathways, contributing to increased consumer interest in understanding how these platforms operate.

What TRT Is and What It Is Not

Understanding what testosterone replacement therapy involves—and what it does not involve—is essential context for evaluating any platform or pathway.

What TRT is:

Testosterone replacement therapy is a prescription medical treatment for men with clinically diagnosed hypogonadism (low testosterone). It involves administration of pharmaceutical testosterone to restore levels to within normal physiological ranges. TRT is an ongoing therapy requiring medical supervision, regular monitoring, and clinical management.

What TRT is not:

TRT is not a supplement, over-the-counter product, or unregulated performance enhancer. It is not appropriate for men with normal testosterone levels. It is not a substitute for addressing lifestyle factors including sleep, exercise, nutrition, and stress management. It is not a guaranteed solution—individual response varies significantly, and not all men with low testosterone experience the same degree of benefit.

Prescription-only status:

TRT requires evaluation by a licensed clinician, laboratory confirmation of low testosterone (generally requiring two morning measurements), assessment of symptoms, and consideration of contraindications. No legitimate pathway dispenses testosterone without this clinical evaluation process.

What Clinical Research Indicates About TRT Benefits and Safety

The clinical evidence base for testosterone therapy has expanded significantly, providing clearer guidance on benefits and safety profiles in men with confirmed hypogonadism.

Evidence from major clinical trials:

According to research published in The New England Journal of Medicine, the Testosterone Trials (TTrials) enrolled men 65 and older with low testosterone and found that one year of testosterone treatment produced moderate benefit with respect to sexual function and some benefit with respect to mood and depressive symptoms, with safety comparable to placebo during the trial period.

According to the TRAVERSE trial, also published in The New England Journal of Medicine, testosterone replacement therapy was noninferior to placebo with respect to major adverse cardiac events in men with hypogonadism and preexisting cardiovascular disease or risk factors during a mean 22-month follow-up. The testosterone group also showed lower incidence of new-onset type 2 diabetes.

What meta-analyses indicate:

According to systematic reviews, TRT in men with confirmed hypogonadism has been associated with increases in lean body mass, reductions in fat mass, improvements in sexual function including libido and erectile function, and improvements in mood and energy. These represent population-level findings; individual results vary and are not guaranteed.

Important research context:

Clinical trial results reflect outcomes in specific study populations with confirmed low testosterone under monitored conditions. They represent averages across groups, not predictions for any individual. Benefits documented in research occurred in men with diagnosed hypogonadism—not in men with normal testosterone levels.

How Low Testosterone Diagnosis Is Generally Determined

Clinical guidelines provide frameworks for determining when TRT may be appropriate.

Symptoms associated with low testosterone:

According to clinical literature, symptoms that may prompt evaluation include persistent fatigue not explained by other causes, reduced libido or sexual function changes, difficulty maintaining muscle mass or increased body fat, mood changes including irritability or low motivation, cognitive symptoms such as difficulty concentrating, and sleep disturbances.

Laboratory requirements:

Clinical guidelines generally require confirmation of low testosterone through at least two morning blood tests (testosterone levels exhibit circadian variation and are typically highest in the morning). Most guidelines define low testosterone as total testosterone below 300 ng/dL, though some use different thresholds.

The diagnostic combination:

According to the American Urological Association and Endocrine Society guidelines, diagnosis of hypogonadism appropriate for TRT consideration generally requires both symptomatic presentation and laboratory confirmation—not symptoms alone or low levels alone.

What else may cause similar symptoms:

Before attributing symptoms to low testosterone, other potential causes are typically considered, including thyroid dysfunction, sleep apnea, depression, chronic stress, nutritional deficiencies, and medication side effects. Comprehensive evaluation considers these possibilities.

Telehealth vs. Clinic-Based Pathways: Neutral Comparison

Men researching TRT options are often comparing telehealth platforms with traditional clinical pathways. Each approach has characteristics that may align better with different priorities.

Telehealth TRT platforms:

Telehealth platforms facilitate TRT evaluation and management through online consultation, coordinated laboratory testing, and home delivery of prescribed medications. This approach offers convenience and accessibility, particularly for men in areas with limited specialist availability or those who prefer avoiding in-person visits.

Considerations: Telehealth evaluation does not include physical examination. Men with complex medical histories may benefit from in-person specialist assessment. Insurance coverage varies and is often not accepted by telehealth platforms.

Traditional clinical pathways (urologist, endocrinologist, primary care):

In-person evaluation provides comprehensive assessment including physical examination, detailed medical history review, and direct specialist interaction. Insurance coverage is more commonly available through traditional pathways.

Considerations: Access may be limited by wait times and geographic constraints. Some primary care providers are less experienced with TRT management. Multiple in-person visits may be required.

Neither pathway is universally superior. The appropriate choice depends on individual medical complexity, insurance considerations, geographic access, and personal preference for virtual versus in-person care. This analysis does not recommend one pathway over another; it outlines structural differences so readers can make informed decisions with their healthcare provider.

Fridays Platform Overview: What Published Program Information Indicates

Based on publicly available information from the Fridays website, the following describes the platform’s published program structure.

Platform role clarification:

According to the company’s terms, Fridays functions as a telehealth platform facilitating connections between patients and healthcare providers. Fridays itself is not a healthcare provider. The platform is operated by Thrive Health, Inc.

Clinician role:

Licensed medical providers contracted through clinical practice groups review patient information and laboratory results to determine whether prescriptions are clinically appropriate. Prescription decisions rest entirely with the evaluating clinician. No prescription is guaranteed.

Pharmacy role:

Prescriptions are fulfilled by licensed U.S. pharmacies. According to the Fridays website, partner pharmacies include RedRock Pharmacy, Health Warehouse, Precision Compounding Pharmacy, and Triad Rx.

This three-entity structure—platform, clinician, pharmacy—ensures separation between the technology platform, clinical decision-making, and medication dispensing.

Delivery format options:

According to the company, Fridays offers testosterone in two formats:

Injectable testosterone: Subcutaneous injection, typically self-administered. According to the company, this is positioned as the “most popular” option.

Oral testosterone: Daily dissolvable tablets absorbed through the oral mucosa. According to the company, this is positioned as a needle-free alternative.

Additional options:

According to the company, the platform also offers enclomiphene (for men seeking to preserve fertility while addressing low testosterone) and anastrozole (for estrogen management when clinically indicated).

Pricing context (according to the company):

Fridays’ published program pages indicate subscription-based access pricing may begin around a stated monthly fee, with medication costs (if prescribed) billed separately and varying by formulation and dose. Pricing, availability, and terms can change and should be confirmed directly on the official Fridays page.

Men evaluating this platform can view the current TRT program offer (official Fridays page) to review current details.

Delivery Formats: Injectable vs. Oral Testosterone

Men evaluating TRT options often compare delivery methods. Each format has characteristics that may align better with different preferences.

Injectable testosterone:

Injectable testosterone has the longest track record and most extensive pharmacokinetic data among TRT delivery methods. According to clinical literature, subcutaneous administration has become increasingly common alongside traditional intramuscular routes, with studies showing comparable absorption profiles.

Characteristics: Weekly or more frequent self-injection at home. Consistent absorption when properly administered. Requires comfort with self-injection technique.

Oral testosterone:

Oral testosterone formats using buccal or sublingual delivery avoid the first-pass liver metabolism that limited earlier oral formulations.

Characteristics: Daily dosing integrates into existing routines. Needle-free administration. Requires consistent daily compliance.

Neither format is universally superior. The appropriate choice depends on individual comfort with injections, dosing preference (weekly vs. daily), and clinical response. The prescribing clinician can provide guidance based on individual circumstances.

Safety and Monitoring: What Is Generally Involved

TRT requires ongoing monitoring to manage potential effects and ensure appropriate dosing.

What is often monitored:

According to clinical guidelines and the Fridays documentation, monitoring during TRT often includes testosterone levels to assess adequacy of replacement, hematocrit to monitor red blood cell production (testosterone stimulates erythropoiesis), PSA in men over 40 as part of prostate health monitoring, and other markers as clinically indicated.

Potential effects:

According to clinical literature, effects associated with TRT may include increased hematocrit (requiring monitoring and potential intervention if levels become elevated), acne or skin changes, testicular volume reduction (external testosterone reduces signals driving testicular function), and fertility impact (TRT typically suppresses sperm production).

Contraindications and cautions:

According to clinical guidelines, situations requiring careful consideration include history of prostate cancer or significantly elevated PSA, history of breast cancer, severe untreated sleep apnea, uncontrolled heart failure, elevated baseline hematocrit, active desire for fertility, and history of blood clots.

This safety overview is not exhaustive. Men considering TRT should discuss their complete medical history with the evaluating clinician.

According to the company, Fridays’ program includes scheduled lab monitoring as part of the subscription structure.

Who Fridays TRT May Fit vs. Who Should Consider Alternatives

Self-assessment of alignment with platform characteristics helps men determine appropriate pathways.

Fridays TRT may align well with men who:

• Have symptoms consistent with low testosterone and want to pursue clinical evaluation through a telehealth pathway.
• Value the convenience of online consultation, coordinated lab work, and home delivery.
• Want format flexibility with both injectable and oral options available through one platform.
• Are comfortable with subscription-based pricing and understand that medication costs are separate.
• Recognize that prescription approval depends on clinical evaluation and is not guaranteed.

Other pathways may be preferable for men who:

• Have complex medical histories including cardiovascular disease, history of prostate cancer, severe sleep apnea, or other conditions warranting in-person specialist evaluation.
• Prefer or require insurance coverage for TRT costs.
• Have active fertility goals and want comprehensive fertility-focused care (though enclomiphene is available through Fridays for fertility preservation).
• Prefer in-person medical care and direct specialist relationships.
• Have normal testosterone levels—TRT is not appropriate for men without confirmed low testosterone.

Questions to Ask Any TRT Provider

Men evaluating any TRT pathway—telehealth or clinic-based—may find these questions helpful:

• What laboratory tests are required before any prescription decision is made?
• How are testosterone levels and hematocrit monitored during treatment?
• Are medications compounded preparations or FDA-approved branded products?
• What are total monthly costs including subscription fees and medication costs if prescribed?
• What follow-up cadence does the clinician use for ongoing management?
• What happens if I do not qualify for a prescription based on lab results?
• How is fertility addressed if that is a concern?
• What is the process for adjusting treatment if needed?

Contact Information

According to the company’s website:

• Phone: (484) 715-9081
• Email: support@joinfridays.com
• Address: 17322 Murphy Ave, Irvine, CA 92614
• Website: joinfridays.com/testosterone

The legal entity operating Fridays is Thrive Health, Inc.

Final Perspective on “Best TRT Injection” Evaluation

This “best” framework is about how consumers can compare access pathways and published program structure—not about medical outcomes, which depend on individualized clinical care.

Men searching for “best TRT injection” during the New Year period are typically seeking to validate whether prescription testosterone therapy is legitimate, understand how telehealth platforms operate, and determine whether their symptoms might warrant clinical evaluation.

What this analysis provides:

Context on why these searches surge during resolution season. Clarification of what TRT is and what clinical research indicates. Explanation of how diagnosis is generally determined. Neutral comparison of telehealth versus clinic-based pathways. Overview of Fridays’ published program structure. Framework for self-assessing pathway alignment. Questions to guide evaluation of any provider.

What this analysis does not provide:

Medical advice or recommendations. Guaranteed outcomes or timelines. Endorsement of any pathway as clinically superior. Guidance on whether any individual should pursue TRT.

Men who determine that evaluation may be appropriate based on their symptoms and circumstances can view the current TRT program offer (official Fridays page) to review Fridays’ published program details, or consult with their primary care provider, urologist, or endocrinologist to discuss whether clinical evaluation is warranted.

Disclaimers

Content and Medical Disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Testosterone replacement therapy is a prescription treatment that requires evaluation by a licensed clinician. The information provided here does not replace the professional judgment of your healthcare provider. No information in this article should be construed as medical advice or as a recommendation to pursue any specific treatment.

“Best” Definition: In this article, “best” reflects consumer search behavior and refers to evaluation criteria such as prescription eligibility requirements, delivery format options, lab monitoring structure, and transparency of publicly available program details. It does not mean clinical superiority, guaranteed results, or medical advice.

Clinical Research Context: References to clinical research findings describe population-level outcomes from studies in men with confirmed hypogonadism under monitored conditions. Individual results vary significantly and are not guaranteed. Clinical trial outcomes do not predict results for any specific individual.

Platform Role Clarification: According to the company’s terms, Fridays is a telehealth platform facilitating connections between patients and healthcare providers. Fridays itself is not a healthcare provider. Prescription decisions are made by independent licensed clinicians based on clinical evaluation. No prescription is guaranteed.

Results May Vary: Individual results with testosterone replacement therapy vary based on factors including age, baseline testosterone levels, symptom profile, lifestyle factors, consistency of treatment, genetic factors, and other individual variables. Response to therapy is not guaranteed.

FTC Affiliate Disclosure: This article contains affiliate links. If you engage with these links and subsequently make a purchase, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. All descriptions are based on publicly available information and published clinical research.

Pricing Disclaimer: Pricing information referenced in this article is based on publicly available program information at the time of publication (December 2025) and is subject to change. According to the company, medication costs are separate from subscription fees and vary based on prescribed formulation. Current pricing, availability, and terms should be confirmed directly on the official Fridays website.

Publisher Responsibility Disclaimer: The publisher has made reasonable efforts to ensure accuracy based on publicly available information at the time of publication. We do not accept responsibility for errors, omissions, changes to program terms, or outcomes resulting from use of the information provided. Readers are encouraged to verify all details directly with Fridays and their healthcare provider.

Insurance Note: According to the company, Fridays does not accept government insurance. Coverage through private insurance or HSA/FSA plans varies; verify eligibility with your specific plan administrator.

CONTACT: Phone: (484) 715-9081
Email: support@joinfridays.com

Best SARM for Bulking and Muscle Growth 2026 – A Guide to SARMs Stacks for Cutting, Strength, Endurance & Recovery” SARMs Launched By Crazy Bulk




Best SARM for Bulking and Muscle Growth 2026 – A Guide to SARMs Stacks for Cutting, Strength, Endurance & Recovery” SARMs Launched By Crazy Bulk

The Best SARMS for Strength, Cutting, Muscle Growth, Body Building & Recovery – A Guide to SARMs: Definition, Side Effects and Dangers

New York City,, Dec. 27, 2025 (GLOBE NEWSWIRE) —

Crazy Bulk Brands has unveiled Best SARM for Bulking and Muscle Growth supplements that aim to reshape how men and women approach bodybuilding management, fitness, and overall health in 2026. Known for formulating safe, science-backed products, Crazy Bulk Brands has become a leader in the nutritional supplement space. 

In 2026, fitness enthusiasts looking to gain serious size without illegal substances are turning to the best SARM-inspired solutions for bulking and muscle growth by CrazyBulk. Designed as legal, stimulant-free alternatives, these advanced formulas aim to support lean muscle gains, improved strength, and faster recovery while fitting modern fitness and safety standards.

CrazyBulk’s SARM-style bulking supplements work by promoting protein synthesis and nitrogen retention—two key factors for building dense, quality muscle. Unlike traditional SARMs, these products are non-hormonal and legally compliant, making them suitable for athletes, gym-goers, and bodybuilders who want results without risking bans or health concerns.

Perfect for hard gainers and experienced lifters alike, CrazyBulk’s 2026 bulking range pairs best with a calorie-surplus diet and progressive training. The result is cleaner mass, better endurance, and sustainable muscle growth—making it a smart, Google-approved choice for next-generation bulking goals.

In this comprehensive guide, we explore why choosing the Best SARM for Bulking and Muscle Growth 2026 for men matters, how these supplements work, and which products from Crazy Bulk’s lineup deliver real results.

With their amazing muscle hypertrophy and muscle definition propensity, SARMs have ultimately taken over the market for anabolic steroids.

Bodybuilding enthusiasts who once placed their blind trust in artificial hormones have now shifted to selective androgen receptor modulators to complement their bulking and cutting cycles.

Visit the Official Website for the Best SARM for Bulking and Muscle Growth 2026

Why “Best SARM for Men” Matters for Bulking, Muscle Growth, and Fitness Goals

Choosing the Best SARM for Men matters because men pursuing bulking and muscle growth need targeted support for strength, recovery, and lean mass development. High-quality SARM-inspired supplements are designed to enhance protein synthesis and muscle endurance, helping men train harder and recover faster without relying on illegal anabolic steroids. For fitness goals like clean bulking, improved performance, and better body composition, the right formula can make a measurable difference. Legal SARM alternatives from trusted brands such as CrazyBulk offer non-hormonal support that aligns with modern safety and compliance standards. When combined with proper training and nutrition, the best SARM options help men achieve consistent gains, improved stamina, and long-term fitness success while minimizing unwanted risks.

Many prefer SARMs for their promising safety profile and dosing practices, which are evidently lacking in steroids.

As they don’t endanger health, they are rising to the top of the priority list for health-conscious bodybuilders and athletes.

Top Benefits of Muscle Building Supplements for Men by CrazyBulk SARMs

Muscle-building supplements by CrazyBulk SARMs offer powerful support for men aiming to gain lean muscle and boost performance. These advanced formulas help enhance protein synthesis, leading to faster muscle growth and improved recovery after intense workouts. They can increase strength and endurance, allowing you to train harder and longer. Many also support nitrogen retention, which is essential for maintaining muscle mass during bulking phases. In addition, CrazyBulk SARMs help improve overall workout performance while minimizing fatigue. When paired with a balanced diet and consistent training, these supplements make it easier for men to achieve stronger, leaner, more defined muscles safely and effectively.

Best SARM for Muscle Growth and Endurance by CrazyBulk

For serious gains in both muscle growth and endurance, CrazyBulk’s SARM-style formulas offer powerful, legal alternatives that support lean mass development and sustained performance. These supplements help boost protein synthesis, enhance strength, and improve recovery, allowing you to train harder and longer. With increased stamina and reduced fatigue, CrazyBulk’s SARM-inspired products are ideal for athletes and fitness enthusiasts seeking stronger workouts and faster, more efficient muscle gains—safely and effectively.

Visit the Official Website for the Best SARM for Bulking and Muscle Growth 2026

Best SARMs for Over 50

For men over 50 seeking strength, muscle maintenance, and improved vitality, CrazyBulk’s SARM supplements offer safe, legal support. These formulas help promote lean muscle growth, enhance endurance, and support joint comfort—key benefits for aging athletes. By boosting protein synthesis and recovery, they help maintain strength and performance without harsh hormones. Ideal when combined with proper nutrition and age-appropriate training for lasting fitness results.

Ingredients That Actually Work: What Science Says

Science shows that proven ingredients like essential amino acids, plant-based adaptogens, nitric oxide boosters, and bioavailable minerals play a real role in muscle growth, endurance, and recovery. These compounds help support protein synthesis, improve blood flow, and reduce workout fatigue. High-quality formulas from trusted brands such as CrazyBulk focus on clinically studied ingredients, ensuring effective, safe, and results-driven support when paired with proper training and nutrition.

What are SARMs?

SARMs may appear as some substances encompassing performance- and physique-enhancing properties, but there is more to these therapeutic compounds.

Essentially, they are anabolic compounds that instigate anabolic activity through their binding affinity to androgen receptors in muscles and bones. And so, they can medically assist people in managing conditions like osteoporosis, muscular dystrophy, prostate cancer, and more.

Now, this may appear to be a mechanism similar to anabolic steroids, but there is a twist!

SARMs use a restricted approach, while binding and steroids do not. They initiate a response by targeting the androgen receptors of muscles and bones, whereas steroids also target other organs.

As a result of their tissue-selective mechanism, they successfully yield your desired muscle- and strength-building progress without stressing other organs.

By following SARMs cycle via pills or injectable administration, you can:

1. Grow fibrous muscle mass and increase size
2. Build strength and bust through performance limits
3. Burn fat, lose weight, and attain optimum muscle definition

 Best SARMs By Crazy Bulk

Similar to anabolic steroids, prohormones, and other anabolic compounds, SARMs come in different kinds.

1. RAD 140 And MK 677 Stack – Best Sarms For Bulking And Muscle Growth
2. Ligandrol And Ibutamoren Stack – Best Sarms For Muscle Mass, Strength, And Performance
3. Ostarine And Cardarine Stack – Best Sarms For Cutting and Weight Loss

There are some focusing on the bulking side of the bodybuilding spectrum, some on performance, and others on shaping mass. Overall, there are many kinds and varieties for you to choose from.

Within these categories there are subcategories of SARMs that work more powerfully than others. To identify the ones that best suit your fitness goals, you need to evaluate them, keeping factors like their anabolic index in mind.

To help you identify, let us first discuss these categories and highlight the ones offering extraordinary promise:

Best SARMs in the market by crazy bulk

1. SARMs for bodybuilding and muscle growth:

SARMs that exclusively work for muscle hypertrophy, that is, the enlargement of muscle, are referred to as “bulking SARMs”. In general, these are common choices for mass gainers during their off-season. However, athletes also count on them for higher aesthetics and increased capacity to perform.

Bulking SARMs work to increase nitrogen retention, which supports the process of protein synthesis in the body.

The process enables the muscle to store an increased amount of protein, which serves as the building block for expanding muscular size. Protein fuels the healing and proliferation of muscle fibers after thewear and tear from intense training. Continuous and efficient recovery simplifies the process of bulking, allowing you to flaunt that dramatic puffed up build more rapidly.

These compounds further increase anabolic hormones like testosterone and human growth hormone, which mainly add to their versatility. Testosterone and HGH work for higher bone density, fat loss, raw strength, power output, and growth of R.B.C. Red blood cells nourish and create ATP for muscles, whereas increased fat loss ensures flawlessly sculpted deltoids and abs!

Here are some SARMs that tremendously add value to your muscle-building goals:

1. RAD 140: A great inclusion in the androgen replacement therapy, RAD 140 Testolone supports the enlargement of dry gains and outrageous strength
2. MK 677: The growth hormone secretagogue uplifts HGH to induce monstrous muscle growth and increase leverage at training
3. Ostarine: Ostarine, or Mk-2866, is all about a comprehensive approach towards bodybuilding with crazy muscle growth and power output

SARMs for cutting and fat loss:

SARMs serve as a holistic technique for losing fat and water weight that may be difficult to shed. These are great compounds and the right tools to assist in bringing down the fat percentage and maintaining balanced levels. SARMs that mainly work to cut down on fat while preserving muscle fibers are referred to as “cutting SARMs”.

Visit the Official Website for the Best SARM for cutting and fat loss in 2026

These SARMs are highly accommodating for losing weight and smashing through fitness plateaus.

In addition, bodybuilders and athletes also resort to cutting SARMs to sculpt their muscles and increase their movement capacity. What’s interesting is that these substances only intend to melt down subcutaneous fat and preserve muscle during the catabolic state. As a result, they promote a body with a balanced composition that is both favorable for health and fitness.

In most cases, SARMs lower your fat ratio by instigating thermogenesis and serving as a metabolic modulator. They activate the growth of testosterone, promoting an all-round effect of relentless energy and a perfectly carved body.

Here are some SARMs with a great contribution to your cutting and fat loss goals:

1. Cardarine: In addition to enhancing blood lipids, the PPARD goes a long way in addressing unhealthy pounds and fat levels
2. Ligandrol: Ligandrol is all about replacing fat with quality muscle tissues. The SARM supports muscle fullness without unnecessary fat deposition
3. Ibutamoren: By adding to the concentration of GH and IGF-1, it takes your basal metabolism and fat breakdown to new heights

What is SARM stack?

Professional and advanced-level bodybuilders follow the practice of stacking SARMs all the time. In fact, they believe that after crossing a certain stage, their body responds better to stacking against standalone substances.

Stacking refers to combining different substances with similar or different properties to experience a substantial transformation.

Other than that, many believe that stacking paces up the rate at which they make their desired progress. And so, they constantly explore options to enable their bodies to welcome bigger and better change!

Are SARMs a steroid?

No. SARMs are not the same as anabolic steroids.

SARMs target the same receptor (chemical binding site) in your body as anabolic steroids. But they work in a more specific way. Anabolic steroids can affect all parts of the body, while SARMs target specific places — such as muscles or bones. What’s more, unlike some anabolic steroids that are injected, SARMs are able to be taken by mouth or injected through the skin (transdermally).

Anabolic steroids are also classified as controlled substances due to their potential for dependence and misuse. Although SARMs are not the same as anabolic steroids, they may be regulated like anabolic steroids in the future. This is because they have substantial risks of their own.

Are SARMs safe?

The truth is, it’s unknown if SARMs are safe. They’re still being researched for safety purposes in clinical studies.

With the current data, it hasn’t been determined yet which doses are safe, what all the potential risks are, and who may benefit most from using SARMs. Until effectiveness and safety information is determined through clinical studies, these unapproved products aren’t intended for widespread, unsupervised use.

What’s more, SARMs that are sold online are not regulated by any U.S. agencies. This means there is a risk that the products may be fake or contain different active ingredients altogether. In fact, according to one study, only about half of the products marketed and sold as SARMs contained the correct, labeled ingredients.

Best SARMs stack

When it comes to the “mixing and matching” of SARMs, there are options far beyond our expectations. However, despite the versatility of options, it takes mere expertise to determine which ones complement each other and not react.

Interestingly, here are some best SARMs stacks that you can rely on for your body makeover goals:

1. RAD 140 and MK 677 stack:

RAD 140 ranks highest as a pure muscle booster in the class of bulking SARMs, as does MK 677.

Hence, a combination of these two powerful substances allows the users to grow mega muscle mass in no time.Now, to understand why many take RAD 140 and MK 677 as fusions, let’s first understand their individual roles.

For some technical reasons, MK 677 does not belong to the class of SARM. It is, in fact, a GH secretagogue that essentially assists the body in producing endogenous growth hormone at increased levels. As a result, it can enhance fat loss, metabolic rate, and muscular and bone strength at the same time.

Conversely, Rad 140, which some of us may know by the name Testolone, is a pure selective androgen receptor modulator. Hence, its properties and mechanisms are more relatable to anabolic steroids than those of MK 677. This indicates its tendency to work like testosterone and focus more on muscular growth and power.

Benefits of RAD 140 and MK 677 stack:

This stack is more like amalgamating testosterone and human growth hormone together. And so, together, in a blend, the two SARMs:

• Speedy recovery of muscles and body recomposition
• Grow muscle tissues and inhibit their breakdown
• Enhance composition, ensuring healthy fat loss
• Increased pumps and a significant rise in strength
• Fills up the sleeves with fibrous and hardened muscles

Dosage of RAD 140 and MK 677 stack:

The typical cycle of the two SARMs in combination continues for a period of 8–10 weeks. In general, experts negate the need to follow a PCT in cases where the cycles are shorter than 12 weeks.

However, there is a need to take a 4-week break after completion and before beginning a new cycle.

2. Ostarine and Cardarine stack:

The combination of Ostarine and Cardarine is another popular go-to in the fitness community, especially by weight lifters.

The two SARMs cover most of the essential areas that directly relate to a fuller, iron-hard body.  However, the common purpose of cycling the two in synergy is to provoke fat burning and retention, and build muscle mass at the same time.

As per bodybuilding experts, the former is a SARM whereas the latter is a peroxisome proliferator activated receptor delta. The combination of the two may not be the best choice for muscle growth (if the expectations are too high), but a great one for fat loss. Though, the dynamics may be a bit different in women who can still reap maximum muscle-building effects from the duo.

Essentially, cardarine is not anabolic, hence, expecting significant gains in areas like muscle hypertrophy may lead to disappointment. However, you can treat the stack as a cutting oneand boost its effects through a calorie deficit, weight training, and conscious eating.

Benefits of Ostarine and Cardarine stack:

The two essential SARMs pack a plethora of benefits for you to enjoy. These are:

• Substantial reduction of subcutaneous and visceral fat
• Satisfactory muscle growth in men but impressive in women
• Continuous reduction in fat levels and proportionate slimming
• Balanced composition, intense endurance, and improved vascularity
• Higher level of V02 max with routine cardiovascular training

Dosage of Ostarine and Cardarine stack:

The average duration of the stack is 8 week for men and women, alike. However, people keen to prolong the period can step up to 12 weeks max. Bear in mind that moderate doses of Ostarine goes easy on women. That is, it does not trigger the symptoms of virilization. Hence, they can easy follow the course and saturate their thirst for a bigger, stronger body.

3. Ligandrol and Ibutamoren stack:

The combo of Mk 677 and Ligandrol also comes across as one of the most promising and versatile for gym-goers. As per experts, Ibutamoren offers equal promise to your health in addition to your fitness. It is an orally-active compound, a growth hormone secretagogue, whereas Ligandrol plays its part as a SARM. 

So technically, LGD-4033 works to enhance muscular growth while Ibutamoren promotes the production of growth hormones and IGF-1. Together as a fusion, they promise maximum growth of fat-free muscle with an increased endurance level.

Ligandrol encompasses an impressive 3:1 anabolic-androgenic ratio, which indicates its propensity to jack up muscle growth without causing virilization. That is, it can work favorably for women striving to bulk up without experiencing the conventional male traits. Mk-677, on the other hand, uplifts the concentration of endogenous HGH that actively works to repair microtears in muscles. Besides boosting the recovery rate, the peptide hormone ensures a balanced composition, fast-paced metabolism, a higher workout capacity, and more.

Benefits of Ligandrol and Ibutamoren stack:

There are countless benefits related to the health and bodybuilding areas that follow their use in conjunction. These are:

• Intense aggression in the gym and extended duration of the training
• Repair and construct muscle tissues more quickly and efficiently
• Enlargement of muscular size, hardening, and definition
• Lean, dry, and fibrous muscle volume and healthy composition
• Protection of muscle and positive net protein

Dosage of Ligandrol and Ibutamoren stack:

In general, fitness enthusiasts suggest a cycle ranging from 8-10 weeks, without following post-cycle therapy. However, they must ensure a 4-week break right after their dosing period ends. If they wish to prolong the cycle up to the 12-week limit, PCT will then become a need.

Where to buy the best SARMs online?

As much as deciding the right SARM for your fitness goal, buying SARMs online demands great care. This is because many of the online and physical stores sell diluted and fake strengths of SARMs, and to reap their true essence, it is essential to grab the real substance.

SARMs manufacturers like CrazyBulk are a consistent and reliable name that you can count on for:

• Purity of compounds
• Right dosing instructions
• Discounts and fair prices
• Money-back guarantee
• Extensive assistance
• Natural and complication-free experience
• Oral SARMs for dosing convenience
• Free shipping and unfailing after-care services
• Orders from any region of the globe
• Prescription-free online purchases

Media Contact:

Full Name – Neil Bowers

Company website: https://www.crazybulk.com/

Email: support@crazybulk.com

+1 888-708-6394

Info@allprsolution.com